UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-Q
X QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended October 1, 2017
OR
TRANSITION REPORT PURSUANT TO SECTION 13
OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from _______ to _______
COMMISSION FILE NUMBER 1-3619
----
PFIZER INC.
(Exact name of registrant as specified in its charter)
DELAWARE
(State of Incorporation)
13-5315170
(I.R.S. Employer Identification No.)
235 East 42nd Street, New York, New York 10017
(Address of principal executive offices) (zip code)
(212) 733-2323
(Registrant s telephone number)
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days.
YES X
NO ___
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T ( 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).
YES X
NO ___
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of large accelerated filer, accelerated filer, smaller reporting company, and emerging growth company in Rule 12b-2 of the Exchange Act (check one):
Large Accelerated filer X Accelerated filer ___ Non-accelerated filer ___ Smaller reporting company ___ Emerging growth company ___
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ___
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
YES ____
NO X
At November 6, 2017, 5,960,707,317 shares of the issuer s voting common stock were outstanding.
Table of Contents
PART I. FINANCIAL INFORMATION
Page
Item 1.
Financial Statements
Condensed Consolidated Statements of Income for the three and nine months ended October 1, 2017 and October 2, 2016
Condensed Consolidated Statements of Comprehensive Income for the three and nine months ended October 1, 2017 and October 2, 2016
Condensed Consolidated Balance Sheets as of October 1, 2017 and December 31, 2016
Condensed Consolidated Statements of Cash Flows for the nine months ended October 1, 2017 and October 2, 2016
Notes to Condensed Consolidated Financial Statements
Review Report of Independent Registered Public Accounting Firm
45
Item 2.
Management s Discussion and Analysis of Financial Condition and Results of Operations
46
Item 3.
Quantitative and Qualitative Disclosures About Market Risk
106
Item 4.
Controls and Procedures
106
PART II. OTHER INFORMATION
Item 1.
Legal Proceedings
107
Item 1A.
Risk Factors
107
Item 2.
Unregistered Sales of Equity Securities and Use of Proceeds
109
Item 3.
Defaults Upon Senior Securities
109
Item 4.
Mine Safety Disclosures
109
Item 5.
Other Information
109
Item 6.
Exhibits
110
Signature
111
GLOSSARY OF DEFINED TERMS
Unless the context requires otherwise, references to Pfizer, the Company, we, us or our in this Quarterly Report on Form 10-Q (defined below) refer to Pfizer Inc. and its subsidiaries. We also have used several other terms in this Quarterly Report on Form 10-Q, most of which are explained or defined below:
2016 Financial Report
Financial Report for the fiscal year ended December 31, 2016, which was filed as Exhibit 13 to the Annual Report on Form 10-K for the fiscal year ended December 31, 2016
2016 Form 10-K
Annual Report on Form 10-K for the fiscal year ended December 31, 2016
AAV
Adeno-Associated Virus
ACA (Also referred to as U.S. Healthcare Legislation)
U.S. Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act
ACIP
Advisory Committee on Immunization Practices
ALK
anaplastic lymphoma kinase
Allergan
Allergan plc
Alliance revenues
Revenues from alliance agreements under which we co-promote products discovered or developed by other companies or us
Anacor
Anacor Pharmaceuticals, Inc.
Astellas
Astellas Pharma U.S., Inc.
ASU
Accounting Standards Update
ATM-AVI
aztreonam-avibactam
Avillion
Avillion LLP
Bamboo
Bamboo Therapeutics, Inc.
BMS
Bristol-Myers Squibb Company
CDC
U.S. Centers for Disease Control and Prevention
Cellectis
Cellectis SA
Citibank
Citibank N.A.
cGMPs
current Good Manufacturing Practices
Developed Markets
U.S., Western Europe, Japan, Canada, Australia, South Korea, Scandinavian countries, Finland and New Zealand
EEA
European Economic Area
EH
Essential Health
EMA
European Medicines Agency
Emerging Markets
Includes, but is not limited to, the following markets: Asia (excluding Japan and South Korea), Latin America, Africa, Eastern Europe, Central Europe, the Middle East and Turkey
EPS
earnings per share
EU
European Union
EURIBOR
Euro Interbank Offered Rate
Exchange Act
Securities Exchange Act of 1934, as amended
FASB
Financial Accounting Standards Board
FDA
U.S. Food and Drug Administration
GAAP
Generally Accepted Accounting Principles
GIST
gastrointestinal stromal tumors
GPD
Global Product Development
HER2-
human epidermal growth factor receptor 2-negative
HIS
Hospira Infusion Systems
Hisun
Zhejiang Hisun Pharmaceuticals Co., Ltd.
Hisun Pfizer
Hisun Pfizer Pharmaceuticals Company Limited
Hospira
Hospira, Inc.
HR+
hormone receptor-positive
ICU Medical
ICU Medical, Inc.
IH
Innovative Health
InnoPharma
InnoPharma, Inc.
IPR&D
in-process research and development
IRS
U.S. Internal Revenue Service
IV
intravenous
Janssen
Janssen Biotech Inc.
King
King Pharmaceuticals, Inc.
LDL
low density lipoprotein
LEP
Legacy Established Products
LIBOR
London Interbank Offered Rate
Lilly
Eli Lilly & Company
LOE
loss of exclusivity
MCO
Managed Care Organization
MD&A
Management s Discussion and Analysis of Financial Condition and Results of Operations
Medivation
Medivation, Inc.
Merck
Merck & Co., Inc.
Meridian
Meridian Medical Technologies, Inc.
Moody s
Moody s Investors Service
NDA
new drug application
NovaQuest
NovaQuest Co-Investment Fund V, L.P.
NSCLC
non-small cell lung cancer
NYSE
New York Stock Exchange
OPKO
OPKO Health, Inc.
OTC
over-the-counter
PBM
Pharmacy Benefit Manager
Pharmacia
Pharmacia Corporation
PP&E
Property, plant & equipment
Quarterly Report on Form 10-Q
Quarterly Report on Form 10-Q for the quarterly period ended October 1, 2017
RCC
renal cell carcinoma
R&D
research and development
RPI
RPI Finance Trust
Sandoz
Sandoz, Inc., a division of Novartis AG
Sangamo
Sangamo Therapeutics, Inc.
SEC
U.S. Securities and Exchange Commission
SFJ
SFJ Pharmaceuticals Group
SIP
Sterile Injectable Pharmaceuticals
S&P
Standard and Poor s
Teuto
Laborat rio Teuto Brasileiro S.A.
U.K.
United Kingdom
U.S.
United States
ViiV
ViiV Healthcare Limited
WRD
Worldwide Research and Development
Zoetis
Zoetis Inc.
PART I - FINANCIAL INFORMATION
Item 1. Financial Statements
PFIZER INC. AND SUBSIDIARY COMPANIES
CONDENSED CONSOLIDATED STATEMENTS OF INCOME
(UNAUDITED)
Three Months Ended
Nine Months Ended
(MILLIONS, EXCEPT PER COMMON SHARE DATA)
October 1,
2017
October 2,
2016
October 1,
2017
October 2,
2016
Revenues
13,168
13,045
38,843
39,196
Costs and expenses:
Cost of sales(a)
2,847
3,085
7,980
9,111
Selling, informational and administrative expenses(a)
3,500
3,559
10,233
10,414
Research and development expenses(a)
1,859
1,881
5,346
5,360
Amortization of intangible assets
1,177
968
3,571
2,934
Restructuring charges and certain acquisition-related costs
149
531
377
988
Other (income)/deductions net
51
1,417
(16
2,815
Income from continuing operations before provision for taxes on income
3,585
1,604
11,351
7,575
Provision for taxes on income(b)
727
249
2,287
1,109
Income from continuing operations(b)
2,858
1,355
9,064
6,465
Discontinued operations net of tax
Net income before allocation to noncontrolling interests(b)
2,858
1,355
9,066
6,465
Less: Net income attributable to noncontrolling interests
18
32
25
Net income attributable to Pfizer Inc.(b)
2,840
1,355
9,034
6,440
Earnings per common share basic(b):
Income from continuing operations attributable to Pfizer Inc. common shareholders
0.48
0.22
1.51
1.06
Discontinued operations net of tax
Net income attributable to Pfizer Inc. common shareholders
0.48
0.22
1.51
1.06
Earnings per common share diluted(b):
Income from continuing operations attributable to Pfizer Inc. common shareholders
0.47
0.22
1.49
1.04
Discontinued operations net of tax
Net income attributable to Pfizer Inc. common shareholders
0.47
0.22
1.49
1.04
Weighted-average shares basic
5,951
6,066
5,972
6,095
Weighted-average shares diluted(b)
6,041
6,150
6,057
6,175
Cash dividends paid per common share
0.32
0.30
0.96
0.90
(a)
Excludes amortization of intangible assets, except as disclosed in Note 9A. Identifiable Intangible Assets and Goodwill: Identifiable Intangible Assets.
(b)
Amounts for the three and nine months ended October 2, 2016 have been revised from previously reported amounts to reflect the adoption of a new accounting standard in the fourth quarter of 2016, as of January 1, 2016. For additional information, see Note 1B. Basis of Presentation and Significant Accounting Policies Adoption of New Accounting Standards.
Amounts may not add due to rounding.
See Notes to Condensed Consolidated Financial Statements.
PFIZER INC. AND SUBSIDIARY COMPANIES
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
(UNAUDITED)
Three Months Ended
Nine Months Ended
(MILLIONS OF DOLLARS)
October 1,
2017
October 2,
2016
October 1,
2017
October 2,
2016
Net income before allocation to noncontrolling interests
2,858
1,355
9,066
6,465
Foreign currency translation adjustments, net
878
417
1,352
998
Reclassification adjustments(a)
(3
110
875
417
1,461
998
Unrealized holding losses on derivative financial instruments, net
(50
(126
(149
(970
Reclassification adjustments for realized (gains)/losses(b)
56
150
(393
280
24
(542
(690
Unrealized holding gains on available-for-sale securities, net
384
261
698
740
Reclassification adjustments for realized gains(b)
(278
(112
(181
(129
106
149
518
611
Benefit plans: actuarial losses, net
(103
(82
(41
(101
Reclassification adjustments related to amortization(c)
140
140
448
418
Reclassification adjustments related to settlements, net(c)
38
28
89
76
Other
(76
69
(111
51
(1
155
384
444
Benefit plans: prior service (costs)/credits and other, net
95
(2
182
Reclassification adjustments related to amortization(c)
(46
(45
(138
(127
Reclassification adjustments related to curtailments, net(c)
(3
(8
(14
(14
Other
12
(48
48
(151
54
Other comprehensive income, before tax
938
793
1,669
1,417
Tax provision/(benefit) on other comprehensive income(d)
(80
116
(218
111
Other comprehensive income before allocation to noncontrolling interests
1,018
677
1,888
1,306
Comprehensive income before allocation to noncontrolling interests
3,876
2,031
10,953
7,771
Less: Comprehensive income attributable to noncontrolling interests
19
48
24
Comprehensive income attributable to Pfizer Inc.
3,857
2,032
10,906
7,747
(a)
The foreign currency translation adjustments reclassified into Other (income)/deductions net in the condensed consolidated statements of income primarily result from sale of our 40% ownership investment in Teuto. See Note 2D. Acquisitions, Sale of Hospira Infusion Systems Net Assets, Collaborative Arrangement and Equity-Method Investments: Equity-Method Investments.
(b)
Reclassified into Other (income)/deductions net and Cost of sales in the condensed consolidated statements of income. For additional information on amounts reclassified into Cost of sales, see Note 7F. Financial Instruments: Derivative Financial Instruments and Hedging Activities.
(c)
Generally reclassified, as part of net periodic pension cost, into Cost of sales, Selling, informational and administrative expenses, and/or Research and development expenses, as appropriate, in the condensed consolidated statements of income. For additional information, see Note 10. Pension and Postretirement Benefit Plans.
(d)
See Note 5C. Tax Matters: Tax Provision/(Benefit) on Other Comprehensive Income.
Amounts may not add due to rounding.
See Notes to Condensed Consolidated Financial Statements.
PFIZER INC. AND SUBSIDIARY COMPANIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(MILLIONS OF DOLLARS)
October 1,
2017
December 31,
2016
(Unaudited)
Assets
Cash and cash equivalents
2,779
2,595
Short-term investments
14,146
15,255
Trade accounts receivable, less allowance for doubtful accounts: 2017 $590; 2016 $609
10,002
8,225
Inventories
7,925
6,783
Current tax assets
3,263
3,041
Other current assets
2,158
2,249
Assets held for sale
16
801
Total current assets
40,291
38,949
Long-term investments
7,311
7,116
Property, plant and equipment, less accumulated depreciation: 2017 $15,906; 2016 $14,807
13,505
13,318
Identifiable intangible assets, less accumulated amortization
49,721
52,648
Goodwill
56,078
54,449
Noncurrent deferred tax assets and other noncurrent tax assets
1,858
1,812
Other noncurrent assets
3,388
3,323
Total assets
172,151
171,615
Liabilities and Equity
Short-term borrowings, including current portion of long-term debt: 2017 $3,072; 2016 $4,225
9,448
10,688
Trade accounts payable
3,480
4,536
Dividends payable
1,909
1,944
Income taxes payable
1,003
437
Accrued compensation and related items
1,932
2,487
Other current liabilities
10,446
11,023
Total current liabilities
28,217
31,115
Long-term debt
34,503
31,398
Pension benefit obligations, net
5,531
6,406
Postretirement benefit obligations, net
1,687
1,766
Noncurrent deferred tax liabilities
30,411
30,753
Other taxes payable
4,304
4,000
Other noncurrent liabilities
6,388
6,337
Total liabilities
111,041
111,776
Commitments and Contingencies
Preferred stock
22
24
Common stock
463
461
Additional paid-in capital
83,827
82,685
Treasury stock
(89,421
(84,364
Retained earnings
75,043
71,774
Accumulated other comprehensive loss
(9,164
(11,036
Total Pfizer Inc. shareholders equity
60,770
59,544
Equity attributable to noncontrolling interests
340
296
Total equity
61,110
59,840
Total liabilities and equity
172,151
171,615
Amounts may not add due to rounding.
See Notes to Condensed Consolidated Financial Statements.
PFIZER INC. AND SUBSIDIARY COMPANIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(UNAUDITED)
Nine Months Ended
(MILLIONS OF DOLLARS)
October 1,
2017
October 2,
2016
Operating Activities
Net income before allocation to noncontrolling interests(a)
9,066
6,465
Adjustments to reconcile net income before allocation to noncontrolling interests to net cash provided by operating activities:
Depreciation and amortization
4,695
4,208
Asset write-offs and impairments
326
1,146
Loss on sale of HIS net assets
52
1,422
Deferred taxes from continuing operations
241
(1,335
Share-based compensation expense
595
532
Benefit plan contributions in excess of expense
(1,042
(775
Other adjustments, net
(561
68
Other changes in assets and liabilities, net of acquisitions and divestitures(a)
(3,644
(1,582
Net cash provided by operating activities(a)
9,728
10,151
Investing Activities
Purchases of property, plant and equipment
(1,256
(1,134
Purchases of short-term investments
(6,469
(15,170
Proceeds from redemptions/sales of short-term investments
5,783
20,685
Net proceeds from redemptions/sales of short-term investments with original maturities of three months or less
2,758
6,485
Purchases of long-term investments
(2,526
(4,771
Proceeds from redemptions/sales of long-term investments
2,417
6,915
Acquisitions of businesses, net of cash acquired
(1,000
(17,679
Acquisitions of intangible assets
(188
(96
Other investing activities, net
519
60
Net cash provided by/(used in) investing activities
38
(4,704
Financing Activities
Proceeds from short-term borrowings
7,003
6,397
Principal payments on short-term borrowings
(7,691
(3,321
Net proceeds from/(payments on) short-term borrowings with original maturities of three months or less
555
(963
Proceeds from issuance of long-term debt
5,273
5,031
Principal payments on long-term debt
(4,474
(4,317
Purchases of common stock
(5,000
(5,000
Cash dividends paid
(5,750
(5,496
Proceeds from exercise of stock options
656
946
Other financing activities, net(a)
(223
(192
Net cash used in financing activities(a)
(9,650
(6,915
Effect of exchange-rate changes on cash and cash equivalents
67
(79
Net increase/(decrease) in cash and cash equivalents
184
(1,547
Cash and cash equivalents, beginning
2,595
3,641
Cash and cash equivalents, end
2,779
2,094
Supplemental Cash Flow Information
Non-cash transactions:
Receipt of ICU Medical common stock(b)
428
Promissory note from ICU Medical(b)
75
Cash paid (received) during the period for:
Income taxes
1,424
1,430
Interest
1,101
1,177
Interest rate hedges
(183
(356
(a)
Amounts for the three and nine months ended October 2, 2016 have been revised from previously reported amounts to reflect the adoption of a new accounting standard in the fourth quarter of 2016, as of January 1, 2016. For additional information, see Note 1B. Basis of Presentation and Significant Accounting Policies: Adoption of New Accounting Standards.
(b)
In connection with the sale of HIS net assets to ICU Medical, on February 3, 2017, Pfizer received 3.2 million newly issued shares of ICU Medical common stock initially valued at $428 million and a promissory note in the amount of $75 million. For additional information, see Note 2B. Acquisitions, Sale of Hospira Infusion Systems Net Assets, Collaborative Arrangement and Equity-Method Investments: Sale of Hospira Infusion Systems Net Assets.
Amounts may not add due to rounding.
See Notes to Condensed Consolidated Financial Statements.
PFIZER INC. AND SUBSIDIARY COMPANIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
Note 1. Basis of Presentation and Significant Accounting Policies
A. Basis of Presentation
See the Glossary of Defined Terms at the beginning of this Quarterly Report on Form 10-Q for terms used throughout the condensed consolidated financial statements and related notes of this Quarterly Report on Form 10-Q.
We prepared the condensed consolidated financial statements following the requirements of the SEC for interim reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by U.S. GAAP can be condensed or omitted.
The financial information included in our condensed consolidated financial statements for subsidiaries operating outside the U.S. is as of and for the three and nine months ended August 27, 2017 and August 28, 2016. The financial information included in our condensed consolidated financial statements for U.S. subsidiaries is as of and for the three and nine months ended October 1, 2017 and October 2, 2016.
Revenues, expenses, assets and liabilities can vary during each quarter of the year. Therefore, the results and trends in these interim financial statements may not be representative of those for the full year.
We are responsible for the unaudited financial statements included in this Quarterly Report on Form 10-Q. The interim financial statements include all normal and recurring adjustments that are considered necessary for the fair statement of our condensed consolidated balance sheets and condensed consolidated statements of income. The information included in this Quarterly Report on Form 10-Q should be read in conjunction with the consolidated financial statements and accompanying notes included in our 2016 Form 10-K.
We manage our commercial operations through two distinct business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). For additional information, see Note 13 and Notes to Consolidated Financial Statements Note 18. Segment, Geographic and Other Revenue Information in Pfizer s 2016 Financial Report.
Certain amounts in the condensed consolidated financial statements and associated notes may not add due to rounding. All percentages have been calculated using unrounded amounts.
Our recent significant business development activities include:
On February 3, 2017, we completed the sale of our global infusion therapy net assets, HIS, to ICU Medical. The operating results of HIS are included in our condensed consolidated statement of income and EH s operating results through February 2, 2017 and, therefore, our financial results, and EH s operating results, for the third quarter of 2017 do not reflect any contribution from HIS global operations, while our financial results, and EH s operating results, for the third quarter of 2016 reflect three months of HIS global operations. Our financial results, and EH s operating results, for the first nine months of 2017 reflect approximately one month of HIS domestic operations and approximately two months of HIS international operations, while our financial results, and EH s operating results, for the first nine months of 2016 reflect nine months of HIS global operations. Assets and liabilities associated with HIS are presented as held for sale in the condensed consolidated balance sheet as of December 31, 2016. The HIS assets held for sale are reported in Assets held for sale and HIS liabilities held for sale are reported in Other current liabilities.
On December 22, 2016, which falls in the first fiscal quarter of 2017 for our international operations, we acquired the development and commercialization rights to AstraZeneca s small molecule anti-infectives business, primarily outside the U.S. Commencing from the acquisition date, our financial statements reflect the assets, liabilities, operating results and cash flows of this business, and, in accordance with our international reporting period, our financial results, EH s operating results, and cash flows for the third quarter and first nine months of 2017 reflect approximately three months and eight months, respectively, of the small molecule anti-infectives business acquired from AstraZeneca.
On September 28, 2016, we acquired Medivation for $81.50 per share. Commencing from the acquisition date, our financial statements reflect the assets, liabilities, operating results and cash flows of Medivation. Therefore, Medivation operations are reflected in our financial results, IH s operating results, and cash flows for the third quarter and first nine months of 2017. In accordance with our domestic and international reporting periods, our consolidated financial statements for the third quarter and first nine months of 2016 reflect three business days of Medivation operations, which were immaterial.